Eli Lilly and Co (XPAR:LLY)
€ 98 0 (0%) Market Cap: 97.40 Bil Enterprise Value: 122.86 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 87/100

Eli Lilly and Co at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 02:45PM GMT
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good morning and welcome to our fireside chat this morning with Eli Lilly at the Barclays Global Healthcare Conference. We're pleased to have with us today Patrik Jonsson, President of Lilly USA and Chief Customer Officer. Sara Smith from the Lilly IR team is on the call as well.

There have been companies that have executed well with their portfolio during the pandemic, and there have been companies that have done well in helping address COVID directly. Lilly is one of those few that have done both exceptionally well. And thinking about just kind of how we were thinking 2020 would set up versus how it executed, they've had success across Verzenio, tirzepatide and now some promising results with donanemab for Alzheimer's with data coming this weekend. It's an exciting time at Lilly. So to Patrik and Sara, welcome. Thanks for joining me this morning.

Patrik Jonsson
Eli Lilly and Company - Senior VP, Chief Customer Officer & President of Lilly USA

Thank you very much.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot